AI-Based Clinical Trial Solutions For Patient Matching Market Size, Share and Growth Outlook, 2026

AI-Based Clinical Trial Solutions For Patient Matching Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global AI-Based Clinical Trial Solutions For Patient Matching Market size is forecast to increase from $1133.83 Million in 2026 to $7625.02 Million in 2034 at a CAGR of 26.9% between 2026 and 2034.

The AI-Based Clinical Trial Solutions For Patient Matching market report provides detailed analysis and outlook of AI-Based Clinical Trial Solutions For Patient Matching segments including By Offering (Software & Platforms, Services), By Technology (Machine Learning & Deep Learning, Natural Language Processing, Predictive Analytics, Knowledge Graphs & Semantic Search, Computer Vision), By Data Source (Electronic Health Records, Genomic & Omics Datasets, Medical Imaging Data, Patient Registries & Insurance Claims, Real-World Data ), By Deployment Mode (Cloud-based, On-premise, Hybrid), By Therapeutic Area (Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Metabolic Disorders, Rare Diseases & Genetic Disorders, Immunology), By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Medical Research Institutes, Hospitals & Health Systems), By Offering (Robotic Systems/Platforms, Instruments & Accessories, Software & AI Licenses, Services ), By End User (Hospitals, Ambulatory Surgical Centers, Academic & Research Institutes, Military & Defense Medical Facilities) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

AI-Based Clinical Trial Solutions for Patient Matching Industry Overview

The AI-Based Clinical Trial Solutions for Patient Matching industry is transforming clinical research by leveraging artificial intelligence to improve patient identification, accelerate trial enrollment, and reduce administrative burdens associated with participant screening. Pharmaceutical companies, research institutions, healthcare providers, and clinical trial organizations are increasingly adopting AI-powered platforms to analyze complex patient data, identify eligible candidates, and streamline recruitment workflows. Advances in agentic AI, real-world evidence analytics, and automated screening technologies are improving the efficiency and accessibility of clinical trials across therapeutic areas, particularly in oncology.

Agentic AI Platforms Accelerating Patient Recruitment

Artificial intelligence is significantly improving the speed and accuracy of patient identification for clinical studies. ConcertAI enhanced its CancerLinQ platform through major upgrades powered by its Cara agentic AI technology. The TriaLinQ module automates patient screening for complex biomarker requirements and treatment-line eligibility criteria, enabling more efficient matching of patients to appropriate clinical trials. According to reported outcomes, the platform screens patients 3.3 times faster than traditional manual approaches and can increase clinical trial enrollment by up to 50%. These capabilities demonstrate the growing value of agentic AI systems in managing highly complex patient eligibility assessments while supporting faster recruitment processes.

Strategic Partnerships Expanding Access to Clinical Research

Industry participants are increasingly forming collaborations to broaden patient access to clinical trial opportunities. Massive Bio announced a partnership with TOUCH, The Black Breast Cancer Alliance, and Navigating Trials to improve awareness and accessibility of clinical research programs. The company utilizes AI-driven real-world data analytics to guide patients through the clinical trial journey while helping identify suitable study opportunities. Further strengthening its market position, Massive Bio achieved Digital Medicine Society certification for clinical evidence generation and privacy standards. These developments highlight the growing importance of AI-powered platforms in addressing recruitment disparities and supporting more inclusive participation in clinical research.

Validated Automated Matching Improving Research Efficiency

Academic research continues to demonstrate the effectiveness of AI-driven patient matching technologies. A study published through ASCO Publications validated a semi-automated screening platform capable of achieving 88% prospective accuracy when matching cancer patients to appropriate clinical trials. The implementation delivered significant operational benefits, reducing manual chart review requirements by ten-fold while decreasing overall clinical trial screening time by 41%. Such findings reinforce the role of artificial intelligence in improving trial feasibility assessments, reducing administrative workloads, and accelerating patient enrollment processes. As clinical research becomes increasingly data-intensive, validated AI-powered matching solutions are becoming essential tools for optimizing trial recruitment and enhancing study execution efficiency.

AI-Based Clinical Trial Solutions For Patient Matching Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global AI-Based Clinical Trial Solutions For Patient Matching market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Unlearn.AI, Inc., Deep 6 AI, Mendel.ai, Antidote Technologies, Inc., ArisGlobal LLC, Koneksa Health, Owkin, Inc., myTomorrows, Lind (Lind Asia), Qureight Limited. The AI-Based Clinical Trial Solutions For Patient Matching market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the AI-Based Clinical Trial Solutions For Patient Matching industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth AI-Based Clinical Trial Solutions For Patient Matching Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by AI-Based Clinical Trial Solutions For Patient Matching companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional AI-Based Clinical Trial Solutions For Patient Matching markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

AI-Based Clinical Trial Solutions For Patient Matching Market Competitive Benchmarking and Company Analysis

Leading companies in AI-Based Clinical Trial Solutions For Patient Matching industry include- Unlearn.AI, Inc., Deep 6 AI, Mendel.ai, Antidote Technologies, Inc., ArisGlobal LLC, Koneksa Health, Owkin, Inc., myTomorrows, Lind (Lind Asia), Qureight Limited. The AI-Based Clinical Trial Solutions For Patient Matching market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US AI-Based Clinical Trial Solutions For Patient Matching Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the AI-Based Clinical Trial Solutions For Patient Matching market remains one of the strongest-performing segments in the country.
The US AI-Based Clinical Trial Solutions For Patient Matching Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US AI-Based Clinical Trial Solutions For Patient Matching market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across AI-Based Clinical Trial Solutions For Patient Matching industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian AI-Based Clinical Trial Solutions For Patient Matching markets

Canada's strong AI-Based Clinical Trial Solutions For Patient Matching sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian AI-Based Clinical Trial Solutions For Patient Matching market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany AI-Based Clinical Trial Solutions For Patient Matching Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest AI-Based Clinical Trial Solutions For Patient Matching market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of AI-Based Clinical Trial Solutions For Patient Matching population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany AI-Based Clinical Trial Solutions For Patient Matching industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the AI-Based Clinical Trial Solutions For Patient Matching market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support AI-Based Clinical Trial Solutions For Patient Matching sales through 2034

France AI-Based Clinical Trial Solutions For Patient Matching companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK AI-Based Clinical Trial Solutions For Patient Matching Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of AI-Based Clinical Trial Solutions For Patient Matching distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China AI-Based Clinical Trial Solutions For Patient Matching Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China AI-Based Clinical Trial Solutions For Patient Matching market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of AI-Based Clinical Trial Solutions For Patient Matching industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese AI-Based Clinical Trial Solutions For Patient Matching industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India AI-Based Clinical Trial Solutions For Patient Matching Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian AI-Based Clinical Trial Solutions For Patient Matching market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil AI-Based Clinical Trial Solutions For Patient Matching market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa AI-Based Clinical Trial Solutions For Patient Matching Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

AI-Based Clinical Trial Solutions For Patient Matching Market Segmentation

By Offering
Software & Platforms
Services
By Technology
Machine Learning & Deep Learning
Natural Language Processing
Predictive Analytics
Knowledge Graphs & Semantic Search
Computer Vision
By Data Source
Electronic Health Records
Genomic & Omics Datasets
Medical Imaging Data
Patient Registries & Insurance Claims
Real-World Data
By Deployment Mode
Cloud-based
On-premise
Hybrid
By Therapeutic Area
Oncology
Cardiovascular Diseases
Neurological Disorders
Infectious Diseases
Metabolic Disorders
Rare Diseases & Genetic Disorders
Immunology
By End User
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Academic & Medical Research Institutes
Hospitals & Health Systems
By Offering
Robotic Systems/Platforms
Instruments & Accessories
Software & AI Licenses
Services
By End User
Hospitals
Ambulatory Surgical Centers
Academic & Research Institutes
Military & Defense Medical Facilities

Top Companies in AI-Based Clinical Trial Solutions For Patient Matching Industry

Unlearn.AI, Inc.
Deep 6 AI
Mendel.ai
Antidote Technologies, Inc.
ArisGlobal LLC
Koneksa Health
Owkin, Inc.
myTomorrows
Lind (Lind Asia)
Qureight Limited

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025